U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07239986) titled 'A Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma' on Nov. 14.
Brief Summary: This is a Phase 2 study to evaluate the efficacy and safety of BB102, a highly selective and potent FGFR4 inhibitor, as monotherapy in subjects with advanced or unresectable FGF19-overexpressing hepatocellular carcinoma. This study has two phase: dose escalation phase and expansion phase.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Hepatocellular Carcinoma (HCC)
Intervention:
DRUG: BB102
Oral BB102 Tablets in two dosage
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Broadenbio Ltd., Co.
Disclaimer: Curated...